Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Dexmedetomidine

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Not Applicable (1)

Trial Status

Completed1
Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT07843953Not ApplicableNot Yet Recruiting

Intraoperative Infusion of Dexmedetomidine Versus Lidocaine or Magnesium Sulphate for Enhanced Quality of Recovery After Spine Surgery Fixation

NCT02225184Completed

Impact of Delta Opioid Receptor Gene (OPRD1) Variations on Treatment Outcome in African Americans

Showing all 2 trials

Research Network

Common Treatments

  • Dexmedetomidine1
  • Group L Licocaine1
  • Group M Magnesium Sulphate1

Active Sponsors

  • National Institute on Drug Abuse (NIDA)1
  • Zagazig University1

Top Investigators

Related Conditions

  • Drug Abusedependence1
  • Opioid Free Anesthesia1
  • Polymorphismgenetic1
  • Genetic Underpinning Of Substance Abuse1
  • Spine Fixation Surgeries1

Activity Timeline